New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): Identification and synthesis of N-propyl-8-chloro-6-substituted isoquinolones

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 3, 2011, Pages 971-976

  Trabanco, Andrés A ^a   Duvey, Guillaume ^b   Cid, José María ^a   MacDonald, Gregor J ^a   Cluzeau, Philippe ^b   Nhem, Vanthea ^b   Furnari, Rocco ^b   Behaj, Nadia ^b   Poulain, Géraldine ^b   Finn, Terry ^b   Lavreysen, Hilde ^a   Poli, Sonia ^b   Raux, Alexandre ^b   Thollon, Yves ^b   Poirier, Nicolas ^b   DAddona, David ^b   Andrés, José Ignacio ^a   Lutjens, Robert ^b   Poul, Emmanuel Le ^b   Imogai, Hassan ^b   Rocher, Jean Philippe ^b   more..

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

Allosteric; Glutamate; Metabotropic; mGluR2; PAM

Indexed keywords

METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; QUINOLONE DERIVATIVE;

ARTICLE; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; LIVER MICROSOME; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ALLOSTERIC REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSOMES, LIVER; PYRIDINES; QUINOLONES; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78751643006     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.048     Document Type: Article

References (23)

1. H. Brauner-Osborne, P. Wellendorph, and A.A. Jensen Curr. Drug Targets 8 2007 169
2. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn, and D.D. Schoepp Nat. Rev. Drug Disc. 4 2005 131
3. R. Shigemoto, A. Kinoshita, E. Wada, S. Nomura, H. Ohishi, M. Takada, P.J. Flor, A. Neki, T. Abe, S. Nakanishi, and N. Mizuno J. Neurosci. 17 1997 7503
4. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Nat. Med. 13 2007 1102
5. D.R. Weinberger Nat. Med. 13 2007 1018
6. Kinon, B.J. International Congress on Schizophrenia Research, San Diego 2009.
7. M.L. Woolley, D.J. Pemberton, S. Bate, C. Corti, and D.N.C. Jones Psychopharmacology 196 2008 431
8. M.J. Fell, K.A. Svensson, B.G. Johnson, and D.D. Schoepp J. Pharmacol. Exp. Ther. 326 2008 209
9. J.P. Conn, A. Christopoulos, and C.W. Lindsley Nat. Rev. Drug Disc. 8 2009 41
10. A.A. Trabanco, J.M. Cid, H. Lavreysen, G.J. Macdonald, and G. Tresadern Curr. Med. Chem. 18 2011 47
11. G. Tresadern, J.M. Cid, G.J. Macdonald, J.A. Vega, A.I. de Lucas, A. García, E. Matesanz, M.L. Linares, D. Oehlrich, H. Lavreysen, I. Biesmans, and A.A. Trabanco Bioorg. Med. Chem. Lett. 20 2010 175
12. Empfield, J.; Folmer, J.; WO2007/095024 A1, 2007.
13. Van Wagenen, B.; Ukkiramapandian, R.; Clayton, J.; Egle, I.; Empfield, J.; Isaac, M.; Ma, F.; Slassi, A.; Steelman, G.; Urbanek, R.; Walsh, S. WO/2007021309, 2007.
14. Cacciola, J.; Empfield, J.; Folmer, J.; Hunter, A. M.; Throner, S. WO/2009/148403, 2009.
15. 20) was characterized using a CHO cell line expressing the human mGlu2 receptor.
16. 2, MW = 306.8, HBD = 0, HBA = 4, RB = 3.
17. Kodama, H.; Katsuhira, T.; Nishida, T.; Hino, T.; Tomokazu, T. K. WO2001083421 A1, 2001.
18. P. Beak, S.T. Kerrick, and D.J. Gallagher J. Am. Chem. Soc. 115 1993 10628
19. a = 4.0.
20. Metabolite identification studies revealed that oxidation of the N-propyl chain is the preferred metabolic pathway for most of these compounds.
21. For an analysis of liphophilicicty across different GluR2 PAM chemical series see Ref. 10.
22. 2+ assays using HEK293 cells expressing human mGluR1, 3-8.
23. 50.